Rifampicin resistance after treatment for latent tuberculous infection: A systematic review and meta-analysis

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 8, 2016, Pages 1065-1071

  Den Boon, Saskia ^a   Matteelli, A ^b   Getahun, H ^b  

^a Independent consultant   (Switzerland)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Chemoprophylaxis; Prevention; Rifamycin

Indexed keywords

ETHAMBUTOL; ISONIAZID; PLACEBO; RIFABUTIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG MONITORING; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; LATENT TUBERCULOSIS; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; ADOLESCENT; ADULT; AGED; CHILD; DRUG EFFECTS; FEMALE; MALE; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; ODDS RATIO; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTITUBERCULAR; CHILD; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; LATENT TUBERCULOSIS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMPIN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84978224532     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0908     Document Type: Review

References (17)

1. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. NEngl JMed 2015; 372: 2127-2135.
2. World Health Organization. Guidelines on the management of latent tuberculosis infection. WHO/HTM/TB/2015.01. Geneva, Switzerland: WHO, 2015.
3. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006; 12: 744-751.
4. Van Halsema CL, Fielding Kl, Chihota VN, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS 2010; 24: 1051-1055.
5. Hong Kong Chest Service; Tuberculosis Research Centre, Madras; British Medical Research Council. Adouble-blind placebo-controlled clinical trial of three antituberculosis chemoprohylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: 36-41.
6. Martinson NA, Barnes GL,Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. NEngl JMed 2011; 365: 11-20.
7. Sterling TR, VillarinoME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. NEng JMed 2011; 365: 2155-2166.
8. Gordin F, Chaisson RE, Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons. An international randomized trial. JAMA 2000; 283: 1445-1450.
9. Matteelli A, Olliaro P, Signorini L, et al. Tolerability of twiceweekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: A pilot study. Int JTuberc Lung Dis 1999; 3: 1043-1046.
10. Johnson JL, Okwera A, Hom DL, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15: 2137-2147.
11. Uplekar M, Weil D, Lönnroth K, et al. WHO's new end TB strategy. Lancet 2015; 385: 1799-1801.
12. Getahun H, Matteelli A, Abubakar I, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J2015; 46: 1563-1576.
13. Getahun H, Granich R, Sculier D, et al. Implementation of isoniazid preventive therapy for people living with HIV worldwide: Barriers and solutions. AIDS 2010; 24 (Suppl 5): S57-S65.
14. Dooley K, Flexner C, Hackman J, et al. Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations. Antimicrob Agents Chemother 2008; 52: 4037-4042.
15. Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIVrelated tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353: 1843.
16. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol 2009; 17: 183-188.
17. Getahun H, KittikraisakW, Heilig CM, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: Individual participant data meta-analysis of observational studies. PLOS Med 2011; 8: E1000391.